• Depletion of TCRαβ-CD19 cells from haploidentical hematopoietic stem cell (HSC) transplants
• The enrichment of CD34-positive cells
TCRαβ-CD19 depletion enables hematopoietic stem cell transplantations (HSCTs) with “half-match” donors with only half of the tissue antigens (HLA-genes) same with the recipient. This means that it is possible to find a suitable donor for practically all patients needing HSCT.
Recently, there have been encouraging results from pediatric patients receiving αβ-T cell and CD19-B cell depleted transplants (TCRαβ-CD19 depleted HSC transplants). With this cell depletion strategy the cells important for the Graft-versus-leukemia (GVL) and against infections (NK cells and γδ-T cells), are retained in the transplant. Beside the TCRαβ-CD19 depleted HSC transplants, patients may need a CD34 enriched transplant from the same donor to ensure sufficient stem cell yield. Compared to other available strategies, the cell engineered HSC transplants have advantages such as lower toxicity and faster engraftment.
HSCT activities are regulated by the Act of medical use of human organs, tissues and cells (Finnish Tissue Law 101/2001) and the graft selection procedures need authorization and a granted tissue establishment license from the Finnish Medicines Agency (FIMEA).
New cell selection methods can be established upon request.
Production manager Anita Laitinen, PhD; email: anita.laitinen(at)bloodservice.fi
A graft engineering service is available at the Finnish Red Cross Blood Service (Picture: Tero Kyllönen/Yle)